Drug Profile
Research programme: protein-targeted antibody therapies - PolyTherics
Alternative Names: HiPEG™ IFN alpha-2a; Recombinant his-tagged IFN alpha-2a - PolyThericsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PolyTherics
- Class Antibodies; Biological proteins
- Mechanism of Action Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Hepatitis C
Highest Development Phases
- No development reported Hepatitis C; Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in United Kingdom (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom (Parenteral)
- 07 Sep 2010 HiPEG™ IFN alpha-2a is available for licensing for hepatitis C as of 07 Sep 2010. www.polytherics.co.uk